Abstract
Rationale
Clozapine is the gold-standard medicine for treating refractory schizophrenia but there are some notable serious adverse events (AE). We aimed to analyse reported rates of clozapine cardiac and haematological AEs in Australia.
Methods
Using data from the Therapeutic Goods Administration, we examined all reported clozapine AEs (1993–2014) with a specific focus on neutropenia, myocarditis and cardiomyopathy. We related AEs to clozapine-dispensing data in Queensland, scaled up to Australia.
Results
There were 8561 AEs reported: neutropenia (13.7%), myocarditis (9.3%) and cardiomyopathy (3.8%). Reported rates of myocarditis and cardiomyopathy increased after 1999 following a myocarditis case series from Sydney. Cardiomyopathy AE rates have remained stable since then but myocarditis AEs have increased steadily. Neutropenia was more common in women, while cardiomyopathy and myocarditis were more common in men. There were five reported deaths from neutropenia and cardiomyopathy.
Conclusions
The rates of serious AEs (including deaths) are low and likely an underestimate of true rates and need to be considered by clinicians in balancing the risks and benefits. Continued education on the monitoring and treatment of these AEs for consumers, carers and health professionals is essential and reporting these to the relevant national reporting agency is crucial.
Similar content being viewed by others
Change history
23 April 2018
The authors would like to change the statement found in the results section of the abstract from "There were five reported deaths from neutropenia and cardiomyopathy." to "There were five, 13, and two reported deaths from neutropenia, myocarditis, and cardiomyopathy, respectively."
References
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G (2011) An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 72:1439–1444
Alphs LD, Anand R (1999) Clozapine: the commitment to patient safety. J Clin Psychiatry 60(Suppl 12):39–42
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162–167
Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657–665
Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, International Consortium for Blood Pressure G, Diabetes Genetics R, Meta-analysis C, Psychiatric Genomics Consortium Schizophrenia Working G, Roddey JC, McEvoy LK, Desikan RS, Dale AM (2013) Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 92:197–209
Australian Consensus Panel for Treatment-Refractory Schizophrenia (2010) Targeting treatment-refractory schizophrenia: a multidimensional outcomes approach to the diagnosis and management of incomplete recovery. https://www.trsconsensus.com.au. Accessed 10 August 2017
Beck K, Howes O (2013) Optimising treatment of refractory schizophrenia. Psychopharmacology 227:373–374
Committee on Safety of Medicines (1993) Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Prob Pharmacovigil 19:9–10
De Barardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, Cavuto M, Martinotti G, Cicconetti A, Piersanti M, Moschetta F, Di Giannantonio M (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55–62
De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Moller HJ, Gautam S, Detraux J, Correll CU (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10:138–151
Devarajan S, Kutcher S, Dursun S (2000) Clozapine and sudden death. Lancet 355:841
Every-Palmer S, Ellis PM (2017) Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal “slow gut” reactions, and comparison with international drug safety advice. CNS Drugs doi: https://doi.org/10.1007/s40263-017-0448-6
Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609
Fairweather D, Cooper LT Jr, Blauwet LA (2013) Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 38:7–46
Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S (2015) Increasing clozapine dispensing trends in Queensland, Australia 2004-2013. Pharmacopsychiatry 48:164–169
Haas SJ, Hill R, Krum H (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30:47–57
Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions : a systematic review. Drug Saf 29:385–396
Hill G, Harrison-Woolrych M (2008) Clozapine and myocarditis: a case series from the New Zealand intensive medicines monitoring Programme. N Z Med J 121:68–74
Hodge K, Jespersen S (2008) Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. Int J Ment Health Nurs 17:2–8
Holmes N, WMiles W, Wheeler A (2015) Development of user-friendly consumer and health professional resources for the antipsychotic clozapine: a New Zealand example. BMJ Innov 1:17–21
Honigfeld G (1996) Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 47:52–56
Idanpaan-Heikklia J, Alhava E, Olkinuora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193–198
Kilian JG, Kerr K, Lawrence C, Celermajer DS (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841–1845
Lahdelma L, Appelberg B (2012) Clozapine-indduced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 73:837–842
Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA (2017) The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 135:296–309
Layland J, Liew D, Prior D (2009) Clozapine-indiced cardiotoxicity: a clinical update. Med J Aust 190:190–192
Malalagama G, Bastiampillai T, Dhillon R (2011) Clozapine use in Australia. Australas Psychiatry 19:175
MedDRA Maintenance and Support Services Organization (2013) Introductory guide MedDRA version 16.1. Chantilly. https://www.meddra.org/sites/default/files/guidance/file/intguide_16_1_english.pdf. Accessed 22 March 2018
Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R (1999) Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 175:576–580
Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411–422
Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15:1329–1347
Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J (2016) Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology 233:3663–3672
Reinders J, Parsonage W, Lange D, Potter JM, Plever S (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 38:915–922
Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V (2016) Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 15:1193–1203
Robertson J, Newby DA (2013) Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust 199:684–686
Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E (2017) The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf 40:607–614
Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ (2010) Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 71:976–981
Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (2011) Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 128:161–165
Ronaldson KJ, Fitzgerald PB, McNeil JJ (2015) Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132:231–240
Siskind D, McCartney L, Kisely, S (2017a) Clozapine in treatment-resistant schizophrenia, author’s reply. Br J Psychiatry 210:299–300
Siskind DJ, Harris M, Phillipou A, Morgan VA, Waterreus A, Galletly C, Carr VJ, Harvey C, Castle D (2017b) Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 26:325–337
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627
Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8:671–677
Wimberley T, MacCabe JH, Laursen TM, Sorensen HJ, Astrup A, Horsdal HT, Gasse C, Stovring H (2017) Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998
Winckel K, Siskind D, Hollingworth S, Wheeler A (2015) Clozapine-induced myocarditis: separating the wheat from the chaff. Aust N Z J Psychiatry 49:188
Acknowledgements
The authors thank the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the data on adverse events. The authors thank Dr. Jenny Curnow from the University of Sydney for reviewing the haematological death cases. We acknowledge the research assistance of Mr. Andrew Kolomensky.
Funding
This study was funded from existing salaries. Dan Siskind is supported in part by an NHMRC Early Career fellowship (APP1111136). This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest.
Ethics approval
No ethical approval was required as we used only secondary de-identified data sources.
Rights and permissions
About this article
Cite this article
Hollingworth, S.A., Winckel, K., Saiepour, N. et al. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014. Psychopharmacology 235, 1915–1921 (2018). https://doi.org/10.1007/s00213-018-4881-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-018-4881-0